Please use this identifier to cite or link to this item:
Title: Development and preclinical evaluation of diclofenac sodium loaded hydroxyethyl starch nanoformulation for parenteral use
Researcher: Dhanya Narayanan
Guide(s): Deepthy Menon , Manzoor K
Keywords: Clinical Pre Clinical and Health,Multidisciplinary,Nanoscience and Nanotechnology
Inflammation; Etiology; Disease management; Nanotechnology
University: Amrita Vishwa Vidyapeetham (University)
Completed Date: 17/02/2016
Abstract: Inflammation research is gaining immense interest in mainstream medicine since researchers uncover evidence that inflammation ignites and feeds chronic illness. It is a protective response to begin the healing process by removing harmful stimuli, including damaged cells, irritants, or pathogens. Inflammation occurs in various disease conditions such as arthritis, diabetes, cardiovascular, neurological, cancer and other autoimmune diseases. Progression of the disease condition affects major organs of the body including brain, kidneys, liver, lungs, muscle, bones etc. and hence disease management at early stage is essential. Disease is currently managed mainly via non-steroidal antiinflammatory drugs (NSAIDs) and it is estimated that 30 million people intake NSAIDs worldwide. Diclofenac Sodium is the most commonly prescribed NSAIDs with its name on seventy four national essential medical lists (EMLs). Although this drug has proven its efficacy in the treatment of pain and inflammation, it often presents safety and tolerability issues, including serious concerns related to gastro-intestinal (GI), cardiovascular (CV), and renal toxicity. Toxicity of DS results from the high clinical doses administered and the route of drug delivery adopted. Specifically, GI related toxicity is common when the drug is administered orally since diclofenac is a weak acid. The side effects associated with the oral route can be mitigated by adopting parenteral administration. While intravenous drug delivery helps the drug molecules to reach systemic circulation easily and has excellent therapeutic outcome, it is accompanied by a rapid decline in plasma levels and drug clearance. This is primarily due to the short plasma half-life and protein binding of the drug, thereby demanding multiple injections. In this regard, biopolymeric nanodrug delivery systems can be a good alternative to resolve the limitations of intravenous drug delivery. ...
Appears in Departments:Amrita Centre for Nanosciences and Molecular Medicine

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File271.65 kBAdobe PDFView/Open
02_declaration.pdf328.44 kBAdobe PDFView/Open
03_certificate.pdf471.86 kBAdobe PDFView/Open
04_contents.pdf419.56 kBAdobe PDFView/Open
05_acknowledgement.pdf528.53 kBAdobe PDFView/Open
06_abstract.pdf436.77 kBAdobe PDFView/Open
07_list of symbols.pdf228.19 kBAdobe PDFView/Open
08_abbreviation.pdf431.31 kBAdobe PDFView/Open
09_list of figures.pdf536.69 kBAdobe PDFView/Open
10_list of tables.pdf327.94 kBAdobe PDFView/Open
11_chapter 1.pdf2.48 MBAdobe PDFView/Open
12_chapter 2.pdf2.47 MBAdobe PDFView/Open
13_chapter 3.pdf8.45 MBAdobe PDFView/Open
14_chapter 4.pdf5.52 MBAdobe PDFView/Open
15_chapter 5.pdf540.88 kBAdobe PDFView/Open
16_references.pdf659.61 kBAdobe PDFView/Open
17_appendix.pdf860.81 kBAdobe PDFView/Open

Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.